Fundz

Anaheim Bio secures €40 million in Series A financing to advance its drug candidate ANA-1 for calcium pyrophosphate deposition disease into the clinic by 2027.

PRIVATENov 05, 2026

Amount Raised

€40 Million

Round Type

Series A

South HollandBiotechnologyTherapeuticsBiopharma

Investors

Thuja CapitalRV InvestNovartis Venture FundRtwFrazier Life SciencesDroia Ventures

Description

Anaheim Bio launched with an oversubscribed €40 million Series A financing to advance ANA-1, a therapeutic candidate for calcium pyrophosphate deposition disease. This funding will support IND-enabling studies and entry into Phase 1. The financing was backed by several investors, including Droia Ventures and Novartis Venture Fund. ANA-1 aims to address the underlying causes of CPPD, a disease affecting many adults worldwide.

Who to call at Anaheim Bio, and when

A new round usually means Anaheim Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Anaheim Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Anaheim Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Anaheim Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Anaheim Bio

Location

South Holland, Netherlands

About

Anaheim Bio is a preclinical-stage biotechnology company focused on developing novel therapies for calcium pyrophosphate deposition disease (CPPD). Spun out of Alesta Therapeutics, the company is advancing its lead program, a small molecule therapeutic candidate called ANA-1. It aims to directly address the underlying pathology of CPPD, a form of inflammatory arthritis. The company has secured significant backing from Alesta's former investors to support its development efforts.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Anaheim Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Anaheim Bio's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Anaheim Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.